

D2 This application also claims priority benefit from provisional U.S. Appln. No. 60/090,169 (filed June 22, 1998).

IN THE CLAIMS

Kindly enter the following amended claims.

D3 Sub E1
1. (Amended) A method for transcutaneous immunization comprising:

- (a) providing a formulation comprised of at least one molecule which is an antigen derived from a pathogen, wherein said formulation does not include heterologous adjuvant;
- (b) applying said formulation epicutaneously to skin of an organism without penetrating said skin's dermis layer; and
- (c) inducing an antigen-specific immune response in said organism, wherein at least one epitope of said antigen is recognized.

D4 10. (Amended) A method of claim 9, wherein hydration enhances the antigen-specific immune response as compared to application of the formulation without hydration.

D5 58. (Amended) A method of claim 1, wherein the antigen is conjugated to a heterologous molecule which targets an antigen presenting cell.

Kindly cancel claims [✓]43-52 and [✓]64 without prejudice or disclaimer.

Kindly enter the following new claim.

D6 70. (New) A formulation for transcutaneous immunization comprised of at least one molecule which is an antigen or a polynucleotide encoding said antigen, wherein said formulation does not include heterologous adjuvant.